Results were presented by Dr Julie Werenberg Dreier (Aarhus University, Denmark). She said previous studies were not large enough to investigate the long-term consequences of recurrent febrile seizures. In a cohort of 2.1 million children born between 1977 and 2011, a total of 75,593 children (3.6%) were diagnosed with a first febrile seizure between 1977 and 2016. The risk of recurrent febrile seizures was 22.7% after the first febrile seizure, 35.6% after the second febrile seizure, and 43.5% after the third febrile seizure. At 3 years of age, about 90% of all the children with febrile seizures will have presented, according to Dr Werenberg Dreier. She added that the risk of epilepsy increased progressively with the number of admissions with febrile seizures. The 30-year cumulative risk of epilepsy and psychiatric disorders in children who had three or more febrile seizures was 15.8% and 29.1%, respectively. At birth, the 30-year cumulative risk is 2.2% and 17.2%, respectively. Mortality was increased among children with recurrent febrile seizures, but only in those who later developed epilepsy.
1. Werenberg Dreier J, et al. EAN 2019, O3219.
Posted on
Previous Article
« PDD and DLB represent two different disorders Next Article
Factors influencing choice of prophylactic migraine therapy »
« PDD and DLB represent two different disorders Next Article
Factors influencing choice of prophylactic migraine therapy »
Table of Contents: EAN 2019
Featured articles
Letter from the Editor
Alzheimer’s Disease and other Dementias
A necessary shift of focus to the earlier stages of Alzheimer’s
Antipsychotics increase mortality regardless of comorbidity
Epilepsy
Neuroinflammatory pathways as biomarkers and treatment targets
Long-term effect of recurrent febrile seizures
Migraine
The role of neurogenic inflammation in migraine
Multiple Sclerosis
Treating MS from disease onset
Randomised and observational studies comparing treatments
Autologous haematopoietic stem cell transplantation
Neuromuscular Disorders
Parkinson's Disease and other Movement Disorders
Inflammation may change the course of Parkinson’s disease
Opicapone: follow-up on the BIPARK I and II trials
Epigallocatechin gallate does not modify MSA progression
Stroke
Thrombo-inflammation during ischaemia/reperfusion
Related Articles
September 9, 2020
Early edoxaban may be safe after cardioembolic stroke
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com